PubRank

Isabelle Jariel-Encontre

Author PubWeight™ 13.99‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Down-regulation of c-Fos/c-Jun AP-1 dimer activity by sumoylation. Mol Cell Biol 2005 1.55
2 SUMOylation regulates nucleo-cytoplasmic shuttling of Elk-1. J Cell Biol 2004 1.24
3 Ubiquitin-independent proteasomal degradation of Fra-1 is antagonized by Erk1/2 pathway-mediated phosphorylation of a unique C-terminal destabilizer. Mol Cell Biol 2007 1.16
4 c-Fos proto-oncoprotein is degraded by the proteasome independently of its own ubiquitinylation in vivo. Mol Cell Biol 2003 1.06
5 The structural determinants responsible for c-Fos protein proteasomal degradation differ according to the conditions of expression. Oncogene 2003 1.04
6 Heterodimerization with Jun family members regulates c-Fos nucleocytoplasmic traffic. J Biol Chem 2007 0.99
7 Heterodimerization with different Jun proteins controls c-Fos intranuclear dynamics and distribution. J Biol Chem 2010 0.96
8 Interaction with 14-3-3 adaptors regulates the sorting of hMex-3B RNA-binding protein to distinct classes of RNA granules. J Biol Chem 2008 0.94
9 JunB breakdown in mid-/late G2 is required for down-regulation of cyclin A2 levels and proper mitosis. Mol Cell Biol 2008 0.93
10 A novel role for PA28gamma-proteasome in nuclear speckle organization and SR protein trafficking. Mol Biol Cell 2008 0.91
11 Ubiquitin-independent- versus ubiquitin-dependent proteasomal degradation of the c-Fos and Fra-1 transcription factors: is there a unique answer? Biochimie 2007 0.91
12 Multiple degradation pathways for Fos family proteins. Ann N Y Acad Sci 2002 0.80
13 Fos family protein degradation by the proteasome. Biochem Soc Trans 2008 0.80
14 Mechanisms of delivery of ubiquitylated proteins to the proteasome: new target for anti-cancer therapy? Crit Rev Oncol Hematol 2005 0.79
15 Evasion from proteasomal degradation by mutated Fos proteins expressed from FBJ-MSV and FBR-MSV osteosarcomatogenic retroviruses. Biochem Pharmacol 2002 0.75
16 [Proteasomal degradation: from addressing of substrates to therapeutical perspectives]. Med Sci (Paris) 2005 0.75